IMPORTANCE The prevalence of prescription opioids detected in fatally injured drivers has increased markedly in the past 2 decades in the United States. It is unclear whether driver use of prescription opioids plays a role in fatal crash causation.
Introduction
Driving under the influence of drugs is a public health concern in the United States and around the world. [1] [2] [3] [4] [5] In the United States, motor vehicle crashes are the second leading cause of unintentional injury deaths after drug overdose. 6 Reversing the longstanding downward trend, death rates per 100 million vehicle miles traveled increased 2.6% from years 2015 to 2016. 7 Concern about drugged driving has heightened in recent years due in part to increasing permissibility and availability of marijuana, excess consumption of prescription opioids, 5, [8] [9] [10] and highly publicized driving under the influence of drugs-related crashes. 11, 12 Opioid use may result in dizziness, drowsiness, and sedation, which may impair the requisite psychomotor and cognitive skills necessary for safe driving. 4, 5, [13] [14] [15] In addition, opioid use may also impair concentration and attention, decrease alertness, and increase reaction time.
In October 2017, the US federal government declared the opioid epidemic a national public health emergency due to the unabated increase in overdose mortality. In 2016, 11.5 million people aged 12 years or older reported that they had misused prescription opioids in the previous year. 16 Among patients who receive prescription opioids for chronic pain, 21% to 29% misuse them and 8%
to 12% develop an opioid use disorder. 17 Although the overall opioid prescription rate per 100 persons has declined from 72.4% in 2006 to 66.5% in 2016, prescription rates remain high at more than 214 million total annual opioid prescriptions. 16 About 25% of US counties dispense opioid prescriptions enough for their entire respective populations and in some counties prescription rates for opioids are up to 7 times the national rate. 16, 18 The prevalence of prescription opioids detected in drivers who died within 1 hour of crash increased from 1% in 1995 to 7.2% in 2015. 15 Hydrocodone, oxycodone, and morphine are the most commonly detected prescription opioids among fatally injured drivers. 15 Few epidemiological studies have assessed the role of prescription opioids in fatal motor vehicle crash initiation.
Recent reviews of experimental and epidemiological studies have found that driver use of prescription opioids is associated with increased cognitive impairment and crash risk.
14, [19] [20] [21] [22] Nonetheless, studies assessing the risk of opioid use on crash initiation have produced inconsistent results, [23] [24] [25] [26] [27] mainly owing to the increasing prevalence of prescription opioids detected in the general driver population and in fatally injured drivers and differences in research designs and analytical approaches across studies. 14 In the present study, we apply a pair-matched design to a large sample of drivers involved in fatal 2-vehicle crashes to assess the role of prescription opioid use in the initiation of fatal 2-vehicle crashes. The pair-matched design allows us to compare the 2 drivers involved in the same crash based on initiation status while minimizing confounding associated with spatiotemporal and environmental characteristics (eg, weather, road conditions, time of day, day of the week, seasonality, traffic regulations, and law enforcement), thus leading to potentially more accurate estimates of crash initiation risk associated with prescription opioid use than alternative approaches.
Methods

Data Source
Data for this study came from the Fatality Analysis Reporting System (FARS) compiled and maintained by the National Center for Statistics of the National Highway Traffic Safety 27, 29 In the present study, for each 2-vehicle crash, the driver with 1 or more driving errors that led to the crash was treated as crash initiator, whereas the other driver with no errors was treated as noninitiator. The use of driving errors as a proxy measure of crash culpability is preferred to traffic violations because traffic violations may require legal proof and are not uniformly recorded. 31 In addition, the coding of driving errors has been associated with the physical configuration of the crash and has been widely used in epidemiologic studies.
27,31-36
Study Design and Study Participants
The 
Drug Testing Assessments
Currently, 26 US states and the District of Columbia have centralized medical examiner systems, 12
have coroner systems, 3 have county or district medical examiners, and 9 have mixed medical examiner and coroner systems responsible for toxicological testing. 37 Drug tests were conducted using blood and/or urine specimens 28 with liquid or gas chromatography, radioimmunoassay techniques, and mass spectrometry for confirmation. 38, 39 Overall, 93.3% of the drivers included in this study had at least 1 drug test based on whole blood specimens. The FARS database records up to 3 nonalcohol drugs. 39 If a driver tests positive for a drug metabolite, only the parent drug is recorded. 29, 38 In cases where multiple nonalcohol drugs were present, the FARS records the drugs based on the following priority order: narcotics, depressants, stimulants, marijuana, and other drugs. 29, 38 between prescription opioids and alcohol was assessed on the multiplicative and the additive scales. 43 To assess robustness and potential biases, we conducted 3 sensitivity analyses by (1) splitting the data into 2 periods (1993-2004 and 2005-2016) ; (2) restricting the analysis to states that performed toxicological testing on 80% or more of all drivers involved in fatal crashes; and (3) restricting the analysis to drivers who died at the crash scene. All data analyses were performed using SAS, version 9.4 (SAS Institute Inc). Statistical significance was set at P < .05 for 2-tailed tests.
Results
The most common driving error leading to fatal 2-vehicle crashes was failure to keep in lane (7535 (Table 1) . From 1993 to 2016, the prevalence of prescription opioids detected among crash initiators increased from 2.0% to 7.1% (P < .001) and among noninitiators from 0.9% to 4.6% (P < .001) (Figure 2 Table 2) .
Conditional logistic regression modeling revealed that prescription opioid use and alcohol use were important risk factors for fatal 2-vehicle crash initiation ( Table 3) . With adjustment for driver Based on data for drivers who died at the crash scene, the estimated adjusted OR of fatal 2-vehicle crash initiation associated with prescription opioid use was 2.79 (95% CI, 1.71-4.54).
Discussion
Before the opioid epidemic began in the mid-1990s, prescription opioids were rarely implicated in fatal motor vehicle crashes, detected only in approximately 1% of fatally injured drivers. 15 In the past 2 decades, the prevalence of prescription opioids detected in fatally injured drivers has steadily increased to more than 7%. 15 The present study provides compelling evidence that driver use of prescription opioids may double the risk of fatal 2-vehicle crash initiation, independent of demographical characteristics, driving history, and alcohol use. This finding is generally consistent with previous studies. 23, 24 A recent meta-analysis found that prescription opioid use was associated with a 47% increased risk of crash initiation. 14 However, to our knowledge, none of the previous studies examining prescription opioid use and crash initiation used the pair-matched design; thus, they are prone to biases from spatiotemporal and environmental factors.
Results of this study suggest that the increased risk of fatal 2-vehicle crash initiation associated with prescription opioid use is owing to a large extent to increased failure to keep in proper lane.
Specifically, failure to keep in proper lane accounted for more than half (54.7%) of driving errors leading to fatal 2-vehicle crashes committed by drivers testing positive for prescription opioids compared with 40.4% of the errors committed by drivers testing negative for prescription opioids.
The association between prescription opioid use and increased failure to keep in proper lane was reported by Dubois et al. 27 Failure to keep in proper lane, such as crossing the centerline, is a particularly dangerous error and might be attributable to the adverse effects of prescription opioids on alertness and lane tracking ability. 44 Polydrug use and the potential interaction between alcohol and other drugs on driving safety are of increasing concern given that 25% of fatally injured drivers test positive for 2 or more drugs. 39 As expected, the risk of fatal 2-vehicle crash initiation increased with BACs in a dose-response fashion. Concurrent use of prescription opioids and alcohol, however, does not seem to confer any significant interaction on the risk of fatal 2-vehicle crash initiation on either the multiplicative scale or the additive scale. Failure to detect a significant interaction effect between the 2 substances is due in part to the low prevalence of concurrent use of prescription opioids and alcohol in the study sample. The mechanisms through which alcohol and opioids can interact are complex and warrant further research. Biological interactions between alcohol and opioids are dependent on the specific drug type, amount of alcohol, and genetic differences among other factors. For example, acute alcohol consumption can enhance the effects of morphine by inhibiting cytochrome P450 3A4, the enzyme that metabolizes common opioids such as buprenorphine, oxycodone, morphine, and fentanyl. 45 However, chronic alcohol consumption can induce cytochrome P450 3A4, leading to increased morphine metabolism and decreased analgesic effects. 45 Alcohol and opioids may also 13 In light of the mounting evidence linking prescription opioids to motor vehicle crashes, 
Limitations
This study had limitations. First, testing positive for prescription opioids indicates recent use of the medication but does not necessarily imply acute impairment resulting from the medication.
However, unlike marijuana, prescription opioids have a relatively short half-life (<4 hours), which increases the likelihood of impairment given a positive test result. 42 Second, data on opioid dosage and blood concentration are unavailable in the FARS, making it impossible to examine the doseresponse relationship between prescription opioid use and the risk of fatal 2-vehicle crash initiation.
Third, drug-testing data are available for only 47% of the drivers involved in fatal crashes, and drugtesting protocols may vary across states. However, restricting the analysis to fatal 2-vehicle crashes where drug-testing data were available for both drivers, complemented by the pair-matched design, should eliminate any serious information bias resulting from incomplete drug testing and variation in drug-testing protocols across states. Fourth, driving errors are used as a proxy measure of crash initiation and may not sufficiently determine culpability in some crashes. However, driving errors have been associated with crash configuration and have been widely used in crash culpability and driving safety research. [31] [32] [33] [34] [35] [36] This study assesses the association of prescription opioid use with the risk of being culpable of initiating fatal 2-vehicle crashes given being involved in these crashes. The estimated ORs reported in this study should not be used as surrogates for measuring the strength of the association between prescription opioid use and the risk of fatal crash involvement.
Conclusions
Prescription opioids are increasingly involved in fatal motor vehicle crashes. This study provides valuable epidemiologic evidence that driver use of prescription opioids is associated with initiation of fatal 2-vehicle crashes, independent of alcohol use and demographical characteristics. While counseling patients about the risks of opioid analgesics, clinicians should take into consideration these medications' adverse effect on driving safety.
